Pharmaceuticals

A hospital looks to the four-legged to pad its bottom line while improving care for our furry companions

The insights could lead to longer-lasting therapies for the deadliest of skin cancers

By Megan Brooks NEW YORK (Reuters Health) - Patients with advanced colorectal cancer fare better with first-line treatment with FOLFOXIRI (folinic acid, 5-FU, oxaliplatin and irinotecan) plus bevacizumab than with FOLFIRI (folinic acid, 5-FU and irinotecan) plus bevacizumab, according to updated survival results from the Italian TRIBE study.

In Part 1 of this series, the Savvy Psychologist covered 5 ways to get to your destination without leaving fingernail marks in the armrest. Today, we’ll learn why you freak out at 30,000 feet and do a 10-second test to see if you’re prone to panic. Plus, the skinny on Xanax and what to do next

The drugs disrupt mosquitoes' gut bacteria, which appears to make the insects more effective malaria vectors. Christopher Intagliata reports

Several expensive cancer medicines will no longer be available on Britain's state-funded National Health Service (NHS) following an overhaul of an over-budget drug funding scheme

Evolution is helping bacteria bounce back

By selecting for bacteria that can survive only if they make a particular product of interest over multiple iterations, researchers vastly improved yields and decreased production times. Cynthia Graber reports

 

Companies and clinicians turn to ketamine to treat mental-health disorder as pipeline of new drugs dries up

Potential drug kills pathogens such as MRSA—and was discovered by mining "unculturable" bacteria

Medical charities say they have started trials of untested drug treatments on Ebola patients in Liberia and Guinea for the first time in an effort to control an epidemic that has killed more than 8,000 people in the region.

Will a pill at breakfast improve concentration and memory—and will it do so without long-term detriment to your health?